FTC Preparing Suit Against Drug Middlemen Over Insulin Rebates

The Federal Trade Commission is preparing a lawsuit against the three largest drug intermediaries over their use of rebates for insulin and other drugs, according to a person familiar with the probe.

The agency has been investigating whether the rebate practices of insulin manufacturers and three pharmacy benefit managers — units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. — violate federal law, said the person, who asked not to be named discussing an ongoing probe.

The drug intermediaries negotiate with drugmakers and manage prescription plans for employers and health insurers.

The complaint is still being drafted but could be filed this month, the person said. The agency’s five commissioners would need to vote on the lawsuit before it can be filed.

CVS Caremark said in a statement that its members on average pay less than $25 for insulin and blamed drug companies for raising list prices. A representative for Cigna’s Express Scripts unit said members paid less out of pocket for medicines in 2023 than in 2022, even as drugmakers raised prices. UnitedHealth Group declined to comment.

The insulin market is dominated by three manufacturers: Eli Lilly & Co., Sanofi and Novo Nordisk.

States and municipalities have filed suits against pharmacy benefit managers and drugmakers, alleging that they drove up insulin costs for public-sector health plans. Many of those cases have been consolidated in a New Jersey federal court managing the litigation.

On Tuesday, the FTC issued an interim staff report on pharmacy benefit managers, finding that they often steer patients to their own dispensaries, including mail-order and specialty businesses, to “advantage their own pharmacies while excluding rivals.”

The FTC issued a policy statement in June 2022 pledging greater enforcement of a 1936 price discrimination law to target illegal prescription drug rebates.

The Wall Street Journal earlier reported news of the potential lawsuit.

 

Source Link

Recommended Articles

State PBM laws Face ERISA Preemption Challenges in Court

States seeking to limit the power of pharmacy benefit managers are running into legal roadblocks. Every state, as well as the federal government, has enacted PBM legislation over the last decade to rein in an industry accused of anticompetitive business practices. Those efforts have seen mixed results as agencies struggle to enforce requirements and courts ...

Read More

Employer Health Cost Crunch Is Worse Than Projected

There’s new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans. Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing ...

Read More

HHS Finalizes Changes To HIPAA Privacy Rule

HHS' Office for Civil Rights finalized a HIPAA privacy rule change cutting the protected health information request response window to 15 calendar days. The final regulation clarifies individuals can retrieve electronic PHI through health apps when entities can support that format.

Read More

Sutter Health-Allina Health Deal Clears Key Hurdle

Sutter Health and Allina Health have achieved a milestone in their plan to merge. The health systems agreed to invest $2.15 billion as part of a 10-year oversight arrangement that Minnesota Attorney General Keith Ellison (D) announced Monday. The deal has been under state review for months. Under terms of the agreement, Sacramento, California-based Sutter ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square